MEKICS CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,420 KRW | -.--% |
|
-2.22% | -39.35% |
| Jan. 24 | Tranche Update on MEKICS CO., Ltd's Equity Buyback Plan announced on October 30, 2023. | CI |
| Jan. 24 | Tranche Update on MEKICS CO., Ltd's Equity Buyback Plan announced on October 30, 2023. | CI |
| Sales 2022 | 28.75B 20.76M | Sales 2023 | 13.26B 9.57M | Capitalization | 62.56B 45.17M |
|---|---|---|---|---|---|
| Net income 2022 | -2.67B -1.93M | Net income 2023 | -16.12B -11.64M | EV / Sales 2022 | 2.78 x |
| Net cash position 2022 | 12.01B 8.67M | Net cash position 2023 | 625M 451K | EV / Sales 2023 | 4.67 x |
| P/E ratio 2022 |
-34.4
x | P/E ratio 2023 |
-3.88
x | Employees | 98 |
| Yield 2022 |
0.51% | Yield 2023 |
-
| Free-Float | 69.12% |
More Fundamentals
* Assessed data
More news
| 1 week | -2.22% | ||
| 1 month | -10.54% | ||
| 3 months | -23.42% | ||
| 6 months | -40.98% | ||
| Current year | -39.35% |
1 week
2 350.00
2 555.00
1 month
2 350.002 790.00
Current year
2 350.004 120.00
1 year
2 165.006 270.00
3 years
2 165.0017 450.00
5 years
1 527.5024 900.00
10 years
1 525.0024 900.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Cheol Kim
CEO | Chief Executive Officer | 59 | 98-10-31 |
Hyeong-Young Lee
DFI | Director of Finance/CFO | 54 | - |
In-Wook Jeong
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jong-Cheol Kim
CEO | Chief Executive Officer | 59 | 98-10-31 |
Jae-Won Lee
BRD | Director/Board Member | 56 | 18-03-22 |
In-Wook Jeong
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-03-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 2,420 | -.--% | 57,672 |
| 24-05-30 | 2,420 | -1.83% | 151,769 |
| 24-05-29 | 2,465 | -1.99% | 68,349 |
| 24-05-28 | 2,515 | -0.59% | 104,272 |
| 24-05-27 | 2,530 | +2.22% | 98,800 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
MEKICS CO., Ltd is a Korea-based company principally engaged in manufacturing medical equipment. The Companyâs products mainly consist of artificial respirators used for critical patient and newborns, portable artificial respirators used for emergency, high oxygen artificial respirators , continuous positive pressure respirators ,patient monitors used for monitoring patient vital sign , measuring appliance used for measuring oxygen saturation.
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -39.35% | 27.24M | |
| -17.59% | 2.74B | |
| +2.53% | 187M | |
| -16.53% | 80.66M |
- Stock Market
- Equities
- A058110 Stock
